Vimarsana
Biggest News Aggregation in the World

Ivan Jarry News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ivan Jarry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ivan Jarry Today - Breaking & Trending Today

ObvioHealth, Oracle Life Sciences Expand Partnership Globally - Vimarsana News

ObvioHealth, Oracle Life Sciences Expand Partnership Globally

ObvioHealth, a global digital clinical trials company, and Oracle Life Sciences are expanding their partnership globally following the results of a

ObvioHealth reveals new digital therapeutics API - Vimarsana News

ObvioHealth reveals new digital therapeutics API

Virtual research organization, ObvioHealth, has just announced the launch of its application programming interface (API) which it says is tailored specifically for digital therapeutics (DTx) clinical trials.

Why Chemist Warehouse wants to educate customers about clinical trials - Vimarsana News

Why Chemist Warehouse wants to educate customers about clinical trials

Clinical medical trials will run in Chemist Warehouse stores to boost numbers and provide better health to customers as a one-stop-shop.

Digitization Can Optimize the Entire Timeline of a Clinical Trial to Improve Endpoints - Vimarsana News

Digitization Can Optimize the Entire Timeline of a Clinical Trial to Improve Endpoints

Experts have seen the value of technology in the clinical trial space because it helps to remove natural bias that can leads to inaccuracies in data collection.

Related Topics:
Ivan JarryPharmacy Time
Combining Technology, Human Elements Improves Participant Retention in Decentralized Clinical Trials - Vimarsana News

Combining Technology, Human Elements Improves Participant Retention in Decentralized Clinical Trials

Closely monitored, decentralized trials have also been shown to improve electronic patient reported outcomes to 92% compliance, according to ObvioHealth.

Related Topics:
Ivan JarryPharmacy Times